SCOPUS 정보 검색 플랫폼

European Journal of Clinical Pharmacology

Volumn 68, Issue 12, 2012, Pages 1681-1683

Stay vigilant: A glitazone (pioglitazone) can hide a glitazar!

(4) Hillaire Buys, Dominique a Faillie, Jean Luc a Montastruc, Jean Louis b Petit, Pierre a

a MONTPELLIER UNIVERSITY HOSPITAL (France)

b TOULOUSE UNIVERSITY HOSPITAL (France)

Author keywords

[No Author keywords available]

Indexed keywords

FARGLITAZAR; FENOFIBRATE; GLUCOSE; LIPID; MURAGLITAZAR; NAVEGLITAZAR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE; PLACEBO; RAGAGLITAZAR; ROSIGLITAZONE; TESAGLITAZAR;

BINDING AFFINITY; BLADDER CANCER; CANCER RISK; DIABETES MELLITUS; DIABETIC PATIENT; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG CARCINOGENICITY; DRUG EXPOSURE; DRUG MEGADOSE; DRUG RECEPTOR BINDING; DRUG RESEARCH; DRUG SAFETY; DRUG SELECTIVITY; DRUG SURVEILLANCE PROGRAM; DYSLIPIDEMIA; FOOD AND DRUG ADMINISTRATION; GLUCOSE HOMEOSTASIS; GLYCEMIC CONTROL; HUMAN; HYPERPLASIA; INSULIN SENSITIVITY; LETTER; LIPID METABOLISM; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RISK MANAGEMENT; TREATMENT DURATION; TREATMENT PLANNING; UROGENITAL TRACT CANCER; UROLITHIASIS;

ANIMALS; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; OXAZOLES; PPAR ALPHA; PPAR GAMMA; RATS; THIAZOLIDINEDIONES; URINARY BLADDER NEOPLASMS;

EID: 84871270525 PISSN: 00316970 EISSN: 14321041 Source Type: Journal
DOI: 10.1007/s00228-012-1299-1 Document Type: Letter

Times cited : (9)

References (13)

1
- 0141539619
- Pharmacologie des agonistes PPARα et PPARγ et des activateurs mixtes en déveleppement clinique
- Duran-Sandoval D, Thomas AN, Bailleul B, Fruchart JC, Staels B (2003) Pharmacologie des agonistes PPARα et PPARγ et des activateurs mixtes en déveleppement clinique. Med Sci 19:819- 825
- (2003) Med Sci , vol.19 , pp. 819-825
- Duran-Sandoval, D.¹ Thomas, A.N.² Bailleul, B.³ Fruchart, J.C.⁴ Staels, B.⁵

2
- 34547661569
- Safety issues and prospects for future generations of PPAR modulators
- Rubenstrunk A, Hanf R, Hum DW, Fruchart JC, Staels B (2007) Safety issues and prospects for future generations of PPAR modulators. Biochem Biophys Acta 1771:1065-1081
- (2007) Biochem Biophys Acta , vol.1771 , pp. 1065-1081
- Rubenstrunk, A.¹ Hanf, R.² Hum, D.W.³ Fruchart, J.C.⁴ Staels, B.⁵

3
- 26844464709
- Accessed 1 March 2005
- El-Hage J (2004) Preclinical and clinical safety assessments for PPAR agonists. http://www.fda.gov/cder/present/DIA2004/Elhage.ppt. Accessed 1 March 2005
- (2004) Preclinical and Clinical Safety Assessments for PPAR Agonists
- El-Hage, J.¹

4
- 84862556665
- Food and Drug Administration. Accessed 1 October 2010
- Food and Drug Administration (2010) FDA drug safety communication: ongoing safety review of actos (pioglitazone) and potential increased risk of bladder cancer after two years exposure. http://www.fda.gov/Drugs/DrugSafety/ ucm226214.htm. Accessed 1 October 2010
- (2010) FDA Drug Safety Communication: Ongoing Safety Review of Actos (Pioglitazone) and Potential Increased Risk of Bladder Cancer after Two Years Exposure

5
- 80155171575
- Pioglitazone and bladder cancer
- Hillaire-Buys D, Faillie JL, Montastruc JL (2011) Pioglitazone and bladder cancer. Lancet 378:1543-1544
- (2011) Lancet , vol.378 , pp. 1543-1544
- Hillaire-Buys, D.¹ Faillie, J.L.² Montastruc, J.L.³

6
- 84866358522
- Pioglitazone and risk of bladder cancer among diabetic patients in France: A population-based cohort study
- doi:10.1007/s00125-012-2538-9
- Neumann A, Weill A, Ricordeau P, Fagot JP, Alla F, Allemand H (2012) Pioglitazone and risk of bladder cancer among diabetic patients in France: a population-based cohort study. Diabetologia. doi:10.1007/s00125-012-2538-9
- (2012) Diabetologia
- Neumann, A.¹ Weill, A.² Ricordeau, P.³ Fagot, J.P.⁴ Alla, F.⁵ Allemand, H.⁶

7
- 79952007219
- Suppressive effects of acid-forming diet against the tumorigenic potential of pioglitazone hydrochloride in the urinary bladder of male rats
- Sato K, Awasaki Y, Kandori H, Tanakamaru ZY, Nagai H, Baron D, Yamamoto M (2011) Suppressive effects of acid- forming diet against the tumorigenic potential of pioglitazone hydrochloride in the urinary bladder of male rats. Toxicol Appl Pharmacol 251:234-244
- (2011) Toxicol Appl Pharmacol , vol.251 , pp. 234-244
- Sato, K.¹ Awasaki, Y.² Kandori, H.³ Tanakamaru, Z.Y.⁴ Nagai, H.⁵ Baron, D.⁶ Yamamoto, M.⁷

8
- 42249084078
- Urothelial carcinogenesis in the urinary bladder of rats treated with naveglitazar, a gamma-dominant PPAR alpha/gamma agonist: Lack of evidence for urolithiasis as an inciting event
- Long GG, Reynolds VL, Lopez-Martinez A, Ryan TE, White SL, Eldridge SR (2008) Urothelial carcinogenesis in the urinary bladder of rats treated with naveglitazar, a gamma-dominant PPAR alpha/gamma agonist: lack of evidence for urolithiasis as an inciting event. Toxicol Pathol 36:218-231
- (2008) Toxicol Pathol , vol.36 , pp. 218-231
- Long, G.G.¹ Reynolds, V.L.² Lopez-Martinez, A.³ Ryan, T.E.⁴ White, S.L.⁵ Eldridge, S.R.⁶

9
- 70649113652
- Neoplastic and non-neoplastic changes in F-344 rats treated with Naveglitazar, a gamma-dominant PPAR alpha/gamma agonist
- Long GG, Reynolds VL, Dochterman LW, Ryan TE (2009) Neoplastic and non-neoplastic changes in F-344 rats treated with Naveglitazar, a gamma-dominant PPAR alpha/gamma agonist. Toxicol Pathol 37:741-753
- (2009) Toxicol Pathol , vol.37 , pp. 741-753
- Long, G.G.¹ Reynolds, V.L.² Dochterman, L.W.³ Ryan, T.E.⁴

10
- 77249130287
- PPARα and PPARγ are co-expressed, functional and show positive interactions in the rat urinary bladder urothelium
- Egerod FL, Brünner N, Svendsen JE, Oleksiewicz MB (2010) PPARα and PPARγ are co-expressed, functional and show positive interactions in the rat urinary bladder urothelium. J Appl Toxicol 30:151-162
- (2010) J Appl Toxicol , vol.30 , pp. 151-162
- Egerod, F.L.¹ Brünner, N.² Svendsen, J.E.³ Oleksiewicz, M.B.⁴

11
- 60049088271
- Rat urinary bladder carcinogenesis by dual-acting PPARα + γ agonists
- Oleksiewicz MB, Southgate J, Iversen L, Egerod FL (2008) Rat urinary bladder carcinogenesis by dual-acting PPARα + γ agonists. PPAR Res 2008:103167
- (2008) PPAR Res , vol.2008 , pp. 103167
- Oleksiewicz, M.B.¹ Southgate, J.² Iversen, L.³ Egerod, F.L.⁴

12
- 53449086678
- Rosiglitazone, a PPAR gamma agonist: Potent promoter of hydroxybutyl(butyl)nitrosamine-induced urinary bladder cancers
- Lubet RA, Fischer SM, Steele VE, Juliana MM, Desmond R, Grubbs CJ (2008) Rosiglitazone, a PPAR gamma agonist: potent promoter of hydroxybutyl(butyl) nitrosamine-induced urinary bladder cancers. Int J Cancer 123:2254-2259
- (2008) Int J Cancer , vol.123 , pp. 2254-2259
- Lubet, R.A.¹ Fischer, S.M.² Steele, V.E.³ Juliana, M.M.⁴ Desmond, R.⁵ Grubbs, C.J.⁶

13
- 78649715079
- Lack of pharmacokinetic interaction between dapagliflozin, a novel sodium-glucose transporter 2 inhibitor, and metformin, pioglitazone, glimepiride or sitagliptin in healthy subjects
- Kasichayanula S, Liu X, Shyu WC, Zhang W, Pfister M, Griffen SC, Li T, LaCreta FP, Boulton DW (2011) Lack of pharmacokinetic interaction between dapagliflozin, a novel sodium-glucose transporter 2 inhibitor, and metformin, pioglitazone, glimepiride or sitagliptin in healthy subjects. Diabetes Obes Metab 13:47-54
- (2011) Diabetes Obes Metab , vol.13 , pp. 47-54
- Kasichayanula, S.¹ Liu, X.² Shyu, W.C.³ Zhang, W.⁴ Pfister, M.⁵ Griffen, S.C.⁶ Li, T.⁷ Lacreta, F.P.⁸ Boulton, D.W.⁹

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.